Back

Clinical outcome up to 2 years after percutaneous coronary intervention in all-comers with concomitant symptomatic peripheral arterial disease: a pooled analysis in 9,204 randomized trial participants

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Coronary intervention: state of the art, complications, and outcomes Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Miss Tineke Pinxterhuis

Thorax Centre in Medisch Spectrum Twente (MST), Enschede (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Robotic-assisted PCI - insights from a monocenter registry
Doctor J. Rilinger (Freiburg, DE)
Abstract Slides Video
Presentation thumbnail
Peri-interventional ischemic stroke after coronary angiography: a large-scale nationwide cohort analysis from 2006 to 2020
Doctor B. Bay (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Coronary perforation incidence and temporal trends (COPIT): systematic review and meta-analysis
Doctor P. Mikhail (Gosford, AU)
Abstract Slides Video
Presentation thumbnail
Ten years survival benefit of CABG or PCI based on individual prediction
Professor P. Serruys (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Stent length and -diameter and long-term clinical outcomes following percutaneous coronary intervention with drug-eluting stent implantation
Ms N. Van Hemert (Utrecht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Coronary intervention: state of the art, complications, and outcomes

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Three-year outcome after coronary stenting in all-comer patients: Impact of diabetes and peripheral arterial disease
thumbnail
Congress Presentation
The predictors of clinical outcome in the patients undergoing endovascular intervention for lower extremity peripheral arterial disease
thumbnail
Congress Presentation
Categorization of patients with peripheral artery disease by charlson comorbidity index

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources